Dok-7 inhibitors are a class of chemical compounds that target the Dok-7 (Downstream of kinase 7) protein, which plays a crucial role in neuromuscular signaling and the formation of neuromuscular junctions (NMJs). Dok-7 is an adaptor protein that interacts with the muscle-specific kinase (MuSK) and is essential for MuSK-mediated signaling, which is critical for the proper development and maintenance of NMJs. These junctions are the sites where motor neurons communicate with muscle fibers to initiate muscle contraction. By activating MuSK, Dok-7 helps in the clustering of acetylcholine receptors on the muscle membrane, facilitating the transmission of neural signals to muscles. Inhibitors of Dok-7 work by interfering with its ability to interact with MuSK, thereby disrupting the signaling pathways necessary for NMJ formation and function.
The design of Dok-7 inhibitors involves identifying molecules that can specifically bind to regions of Dok-7 that are responsible for its interaction with MuSK or other proteins involved in the signaling cascade. These inhibitors function by preventing Dok-7 from activating MuSK, thereby blocking the downstream processes essential for NMJ assembly and maintenance. Structural studies of Dok-7 have been crucial in identifying the domains necessary for its function, allowing for the development of inhibitors that specifically target its activity without affecting other proteins in the pathway. Dok-7 inhibitors are valuable tools for researchers aiming to study the molecular mechanisms involved in neuromuscular signaling and junction formation. By inhibiting Dok-7, scientists can explore how this protein contributes to the precise coordination of muscle function and neural communication, gaining insights into the regulation of muscle development and maintenance at the molecular level.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that may indirectly affect Dok-7 by inhibiting kinases in related signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, another tyrosine kinase inhibitor, could potentially influence Dok-7 activity by modulating receptor tyrosine kinase signaling. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Erlotinib, an EGFR inhibitor, may have an indirect effect on Dok-7 through the inhibition of epidermal growth factor receptor signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib, a receptor tyrosine kinase inhibitor, could indirectly affect Dok-7 activity by targeting related signaling pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, a dual EGFR and HER2 inhibitor, might influence Dok-7 indirectly through its action on these receptors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a broad-spectrum kinase inhibitor, could potentially impact Dok-7 by targeting multiple kinases in associated signaling pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, might indirectly influence Dok-7 activity through the MAPK/ERK pathway. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, an EGFR inhibitor, could indirectly affect Dok-7 through its effect on epidermal growth factor receptor signaling pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib, a receptor tyrosine kinase inhibitor, may have an indirect influence on Dok-7 by targeting kinases in related signaling cascades. | ||||||